Roche today announced that new results from a number of studies across its industry leading oncology portfolio of approved and investigational medicines will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place from 19-23 October, in Munich, Germany. These data include positive Phase III results from Roche’s cancer immunotherapy development programme across multiple tumour types, positive Alecensa® (alectinib) data from the Phase III ALESIA study and new pivotal data for entrectinib, a tumour-agnostic investigational medicine that targets NTRK gene fusion-positive solid tumours.
“We look forward to presenting the first positive Phase III study of a cancer immunotherapy combination in breast cancer, which showed encouraging results for Tecentriq plus nab-paclitaxel in people with metastatic triple-negative breast cancer, specifically in the PD-L1-positive population,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “We will also share new data from our pivotal analysis of entrectinib for people with NTRK gene fusion-positive solid tumours, an example of our continued commitment to developing next-generation personalised treatments.”
Further information on Roche’s latest progress in its oncology portfolio and unique, multidimensional approach to advancing transformative cancer care, will be featured during the Roche Media Briefing from 08:15 – 10:15 CEST on Friday, 19 October at the Hilton Munich Park Hotel, Munich, Germany. This event is independently organised by Roche and is open to registered journalists. Please note data under embargo at ESMO will not be shown at this event. To register for the independent Roche Media Briefing, please follow this link: http://roche.cvent.com/events/roche-media-briefing-at-esmo-2018/event-summary-22a12025189c478e8896ee4340f9f47f.aspx
